By Hilary Rosselot
Tetra Therapeutics Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Chad Coberly, CEO of Tetra Therapeutics, a Shionogi Group Company, presented about BPN14770, a PDE4 inhibitor, during the Industry Updates keynote session at the 18th International Fragile X Conference. BPN14770 is in Phase 2b/3 trials in Fragile X syndrome with the goal of becoming an FDA-approved treatment for cognition in FXS. Tetra is now enrolling participants in their BPN14770 trial. More information about the trials can be found here.
Chad spoke about the status of Tetra’s Fragile X program, including their Phase 2 trial results, their current Phase 2b/3 BPN14770 trials, and their hopeful timeline for approval. Learn more about Tetra and their BPN14770 trials by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.
My Fragile X Advocacy Journey
NFXF Director of Community Empowerment, Missy Zolecki, shares her recent experience as a consumer reviewer for the Department of Defense Peer Reviewed Medical Research Program
Study: Autonomic and Sensory Functioning in Infants with FMR1 Conditions
Dr. Jane Roberts and the research staff at the Neurodevelopmental Disorders Laboratory at USC are conducting a research study to learn about the development of infants with Fragile X syndrome and Fragile X premutation over the first few years of life.